Generic formulations of imatinib for treatment of Philadelphia chromosome-positive leukemia in pediatric patients

Beitrag in einer Fachzeitschrift


Details zur Publikation

Autorinnen und Autoren: Suttorp M, Metzler M, Millot F, Shimada H, Bansal D, Gunes AM, Kalwak K, Sedlacek P, Baruchel A, Biondi A, Hijiya N, Schultz KR, Schrappe M
Zeitschrift: Pediatric Blood & Cancer
Jahr der Veröffentlichung: 2018
Band: 65
Heftnummer: 12
ISSN: 1545-5009


Abstract

Since the patent for imatinib has expired, the role of generic imatinib (GI) in the management of Philadelphia chromosome-positive (Ph+) leukemia in pediatric patients has had ongoing discussion. Some studies in adults demonstrated that equivalent doses of GI and branded imatinib (BI) result in comparable plasma concentrations and clinical efficacy. However, other studies found that GI users are more likely to stop imatinib, with intolerance and decreased persistence as the main causes. Economic factors also heavily influence GI selection. This article aims to review the present knowledge to support further discussion on the role of GI in the management of pediatric Ph+ leukemia.


FAU-Autorinnen und Autoren / FAU-Herausgeberinnen und Herausgeber

Metzler, Markus PD Dr.
Professur für Kinder- und Jugendmedizin mit dem Schwerpunkt Pädiatrische Onkologie und Hämatologie


Einrichtungen weiterer Autorinnen und Autoren

BC Children's Hospital Research Institute
Centre hospitalier universitaire de Poitiers (CHU de Poitiers)
Keio University / 慶應義塾大学
Northwestern University
Postgraduate Institute of Medical Education and Research
Robert Debré Hospital for Mothers and Children / Hôpital Robert Debré pour la mère et l'enfant
Uludag University
Universitätsklinikum Carl Gustav Carus Dresden
Universitätsklinikum Schleswig-Holstein (UKSH)
University of Milano-Bicocca / Università degli Studi di Milano-Bicocca, UNIMIB
Univerzita Karlova v Praze / Charles University in Prague
Wrocław Medical University / Uniwersytet Medyczny we Wrocławiu


Zitierweisen

APA:
Suttorp, M., Metzler, M., Millot, F., Shimada, H., Bansal, D., Gunes, A.M.,... Schrappe, M. (2018). Generic formulations of imatinib for treatment of Philadelphia chromosome-positive leukemia in pediatric patients. Pediatric Blood & Cancer, 65(12). https://dx.doi.org/10.1002/pbc.27431

MLA:
Suttorp, Meinolf, et al. "Generic formulations of imatinib for treatment of Philadelphia chromosome-positive leukemia in pediatric patients." Pediatric Blood & Cancer 65.12 (2018).

BibTeX: 

Zuletzt aktualisiert 2019-28-03 um 11:08